GLP-1 receptor agonism in Alzheimer's disease after EVOKE: From single hypothesis to stratified program
- 10 September 2026
- journal article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 114 (1) , 84-86
Abstract
The phase 3 EVOKE and EVOKE + trials of oral semaglutide in early Alzheimer's disease missed their primary endpoint and every cognitive or functional secondary endpoint. A recent article by Hölscher revisits extension-phase data and reports partial separation at later timepoints, attributing the failure to limited brain penetration. We argue that attrited extension cohorts bear limited inferential weight and that the biomarker substudy, read in full, complicates a clean disease-modification reading. EVOKE does not refute the cardiometabolic hypothesis but reframes the open questions: which pathways, which patients, and which disease stages are most likely to benefit.Keywords
This publication has 13 references indexed in Scilit:
- Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trialsThe Lancet, 2026
- Tirzepatide versus semaglutide for the prevention of mild cognitive impairment, dementia, and Alzheimer's disease in type 2 diabetes: A real-world, retrospective cohort studyJournal of Diabetes and its Complications, 2026
- Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trialThe Lancet, 2025
- Associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real‐world data in the USAlzheimer's & Dementia, 2024
- Trial of Lixisenatide in Early Parkinson’s DiseaseNew England Journal of Medicine, 2024
- Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trialThe Lancet Neurology, 2023
- NIA‐AA Research Framework: Toward a biological definition of Alzheimer's diseaseAlzheimer's & Dementia, 2018
- Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1.American Journal of Epidemiology, 2016
- A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's DiseaseNew England Journal of Medicine, 2013
- Recommendations for the Primary Analysis of Continuous Endpoints in Longitudinal Clinical TrialsDrug Information Journal, 2008